Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Laboratory Corporation Of America Holdings (LH)
NYSE:LH
Holding LH?
Track your performance easily
Earnings Data
Report Date
Feb 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$3.39Last Year’s EPS
$3.3Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 24, 2024
|% Change Since: 4.27%
|Next Earnings Date:Feb 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and positive outlooks in various segments, including diagnostics and oncology advancements. However, challenges in early development and margin pressures due to acquisitions and weather presented concerns.Company Guidance
During Labcorp's Q3 2024 earnings call, management provided detailed guidance and performance metrics, highlighting a 7% increase in revenue to $3.3 billion compared to Q3 2023. Diagnostics saw a robust revenue growth of 9%, driven by 5% organic growth, while Biopharma Laboratory Services reported a 3% increase, with Central Labs showing a strong 9% growth. Adjusted EPS rose by 4% to $3.50, despite a 40 basis point decline in enterprise margins due to the Invitae acquisition. The trailing 12-month book-to-bill ratio was 1.02, and the company maintained its full-year revenue growth guidance of 6.6% to 7.3%. Labcorp's strategic initiatives, including the LaunchPad savings target of $100 million to $125 million, remained on track, contributing to the overall positive outlook.Strong Financial Performance
Revenue in Q3 2024 was $3.3 billion, an increase of 7% compared to the third quarter of 2023. Adjusted EPS was $3.50, up 4% year-over-year.
Growth in Diagnostics
Diagnostics revenue grew by 9% driven by organic growth of 5%, with contributions from acquisitions.
Advancements in Oncology
Labcorp received FDA marketing authorization for PGDx elio plasma focus Dx, the only kitted pan solid tumor liquid biopsy test, and expanded collaboration with Ultima Genomics.
Invitae Acquisition and Integration
The acquisition of Invitae is on track and expected to be slightly accretive in 2025, with top-line growth of approximately 10%.
Positive Managed Care Relations
Successful negotiations with managed care organizations, resulting in neutral to slightly positive terms for 2025.
---
LH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $219.24 | $229.38 | +4.63% |
| Aug 01, 2024 | $214.13 | $231.97 | +8.33% |
| Apr 25, 2024 | $205.92 | $196.42 | -4.61% |
| Feb 15, 2024 | $225.15 | $219.25 | -2.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Laboratory Corporation Of America Holdings (LH) report earnings?
Laboratory Corporation Of America Holdings (LH) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
What is Laboratory Corporation Of America Holdings (LH) earnings time?
Laboratory Corporation Of America Holdings (LH) earnings time is at Feb 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LH EPS forecast?
LH EPS forecast for the fiscal quarter 2024 (Q4) is $3.39.
---